ZIOPHARM, Inc. Commences Treatment of First Patients in Two Separate Phase I/II Combination Studies of Both Indibulin and Palifosfamide

February 4, 2008 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

NEW YORK--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP), announced today that dosing of the first patient took place in two separate new studies, including:

Twitter
LinkedIn
Facebook
Email
Print

Clinical research Phase I